Ratings Roche Holding AG

Equities

ROG

CH0012032048

Market Closed - Swiss Exchange 11:30:11 2024-04-19 am EDT 5-day change 1st Jan Change
222.1 CHF +0.95% Intraday chart for Roche Holding AG -1.29% -9.16%

Summary

  • According to Refinitiv, the company's ESG score for its industry is good.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • This company will be of major interest to investors in search of a high dividend stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The company's enterprise value to sales, at 3.19 times its current sales, is high.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
-9.16% 197B
A+
+24.60% 654B
C+
+24.08% 552B
B
-5.63% 356B
C+
+15.37% 319B
B-
+7.38% 295B
C+
+3.26% 211B
B+
+0.78% 206B
B-
-9.69% 147B
C+
-6.63% 144B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ROG Stock
  4. Ratings Roche Holding AG